Biofil Chemicals & Pharmaceuticals enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


47.6	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.1	0.1	0.1	0.1	0.0
3.0	3.0	0.5	0.4	0.5
50.6	—	—	—	—
3.0	3.0	0.3	0.3	0.5
₹31.08	—	—	—	—

24.6	24.6	19.3	18.6	17.8
12.3%	12.3%	2.4%	2.4%	2.9%
0.06×	—	—	—	—

1.47×	—	—	—	—
64.47×	—	—	—	—
99.16×	—	—	—	—
34.3	28.4	33.4	40.0	30.0
0.8	0.6	0.8	0.8	1.2
0.5	0.4	0.5	0.4	0.7
—	−0.6	−1.9	2.4	−0.1
−0.8	−0.8	−2.0	2.4	−0.1
—	−0.8	−2.0	2.4	−0.1
—	0.2	0.1	0.0	0.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersMANGALAM VINEETLAB LASA ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹47.6 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	47.6
- Cash, Equiv & ST Investments	0.0	0.1	0.1	0.1	0.1
+ Total Debt	0.5	0.4	0.5	3.0	3.0
Enterprise Value	—	—	—	—	50.6
Net Debt (memo)	0.5	0.3	0.3	3.0	3.0
EV per Share	—	—	—	—	31.08

Total Capital	17.8	18.6	19.3	24.6	24.6
Total Debt/Total Capital	2.93	2.35	2.45	12.28	12.28
Total Debt/EV	—	—	—	—	0.06

EV/Sales	—	—	—	—	1.47
EV/EBITDA	—	—	—	—	64.47
EV/EBIT	—	—	—	—	99.16
Reference Items — Trailing FY Values
Sales	30.0	40.0	33.4	28.4	34.3
EBITDA	1.2	0.8	0.8	0.6	0.8
EBIT	0.7	0.4	0.5	0.4	0.5
Operating Cash Flow	-0.1	2.4	-1.9	-0.6	—
Free Cash Flow	-0.1	2.4	-2.0	-0.8	-0.8
FCFF (free cash flow to the firm)	-0.1	2.4	-2.0	-0.8	—
Capital Expenditure	0.0	0.0	0.1	0.2	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.